Lisa von Moltke, M.D.
Dr. von Moltke has served as a member of our Board since November 2022. Dr. von Moltke has directed successful development programs, led clinical teams, and interacted with regulatory agencies across multiple therapeutic areas. Currently, Dr. von Moltke serves as Executive Vice President and Chief Medical Officer of Seres Therapeutics, a leading microbiome therapeutics company. Prior to joining Seres, Dr. von Moltke served in roles of increasing seniority at Alkermes, Inc., culminating as Senior Vice President and Head of Clinical Development. Previously, Dr. von Moltke was Vice President Clinical Pharmacology at Sanofi/Genzyme Corporation, where she also served as U.S. Head Clinical & Exploratory Pharmacology Sciences (CEP) and Early Development and later as Head CEP for Japan and China regions. Earlier in her career, she was Head, Translational Medicine for the Takeda Oncology Company. Dr. von Moltke has served as President of the American College of Clinical Pharmacology and Editor-in-Chief of The Journal of Clinical Pharmacology. She received a B.A. from Wellesley College and M.D. from Michigan State University, College of Human Medicine.